Your search returned 3 results.

Results
	1.	Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits. [electronic resource] by Stringer, Megan Goodlett, Charles R Roper, Randall J Publication details: Molecular genetics & genomic medicine Sep 2017 In: Molecular genetics & genomic medicine vol. 5 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model. [electronic resource] by Stringer, Megan Abeysekera, Irushi Dria, Karl J Roper, Randall J Goodlett, Charles R Producer: 20160728 In: Pharmacology, biochemistry, and behavior vol. 138 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes. [electronic resource] by Stringer, Megan Abeysekera, Irushi Thomas, Jared LaCombe, Jonathan Stancombe, Kailey Stewart, Robert J Dria, Karl J Wallace, Joseph M Goodlett, Charles R Roper, Randall J Producer: 20180320 In: Physiology & behavior vol. 177 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search